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Objectives The purpose of the study was to evaluate the effect of long-term 1-aderergic receptor (AR) blockade on
left ventricular (LV) remodeling and function in patients with chronic, isolated, degenerative mitral
regurgitation (MR).
Background Isolated MR currently has no proven therapy that attenuates LV remodeling or preserves systolic function.
Methods Thirty-eight asymptomatic subjects with moderate to severe, isolated MR were randomized either to placebo or
1-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years. Magnetic resonance imaging with
tissue tagging and 3-dimensional analysis was performed at baseline and at 6-month intervals for 2 years. Rate
of progression analysis was performed for endpoint variables for primary outcomes: LV end-diastolic volume/body
surface area, LV ejection fraction, LV end-diastolic (ED) mass/ED volume ratio, LV ED 3-dimensional radius/wall thick-
ness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV early diastolic filling rate.
Results Baseline LV magnetic resonance imaging or demographic variables did not differ between the 2 groups. Signifi-
cant treatment effects were found on LV ejection fraction (p  0.006) and LV early diastolic filling rate
(p  0.001), which decreased over time in untreated patients on an intention-to-treat analysis and remained
significant after sensitivity analysis. There were no significant treatment effects found on LV ED or LV end-
systolic volumes, LV ED mass/LV ED volume or LV ED 3-dimensional radius/wall thickness, or LV longitudinal
strain rate. Over 2 years, 6 patients treated in the placebo group and 2 patients in the 1-AR blockade group
required mitral valve surgery (p  0.23).
Conclusions 1-AR blockade improves LV function over a 2-year follow-up in isolated MR and provides the impetus for a
large-scale clinical trial with clinical outcomes. (Molecular Mechanisms of Volume Overload-Aim 1 [SCCOR in
Cardiac Dysfunction and Disease]; NCT01052428) (J Am Coll Cardiol 2012;60:833–8) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.029Degenerative mitral valve disease, usually related to mitral
valve prolapse, is responsible for most cases of isolated
mitral regurgitation (MR) in the United States (1). There is
From the *Department of Medicine and Cardiovascular Disease, University of
Alabama at Birmingham, Birmingham, Alabama; †Department of Biostatistics,
University of Alabama at Birmingham, Birmingham, Alabama; ‡Birmingham Vet-
eran Affairs Medical Center, Birmingham, Alabama; §Department of Cardiovascular
Surgery, University of Alabama at Birmingham, Birmingham, Alabama; and the
Samuel Ginn College of Engineering, Auburn University, Auburn, Alabama. This
study was funded by the National Heart, Lung and Blood Institute Specialized Center
for Clinically Oriented Research (SCCOR) in Cardiac Dysfunction, National
Institutes of Health, Bethesda, Maryland (grant no.: P50HL077100). Drugs and
placebos were supplied by AstraZeneca. The authors have reported that they have no
relationships relevant to the contents of this paper to disclose.Manuscript received August 22, 2011; revised manuscript received March 13, 2012,
accepted April 16, 2012.no effective medical therapy for isolated MR, and therefore,
surgery is recommended in patients with severe MR and
symptoms or evidence of progressive left ventricular (LV)
dysfunction (2,3). The natural history of MR is progressive
LV dysfunction and adverse LV remodeling, eventually
leading to heart failure. Initially, LV dilation and aug-
mented stroke volume occur, facilitated by an increase in
preload and by ejection into the relatively low-pressure left
See page 839
atrium. These changes are accompanied by increased sympa-
thetic drive early in MR in both animal models (4,5) and
humans (6). However, prolonged excessive adrenergic stimu-
lation has a cytotoxic effect on cardiomyocytes (7), resulting in
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1-Receptor Blockade for Chronic MR August 28, 2012:833–8increased LV end-systolic dimen-
sion or volume and wall stress. In
the canine model of isolated MR,
chronic 1-adrenergic receptor
(AR) blockade has been shown to
improve cardiomyocyte and LV
function (8,9). In patients with
severe MR and normal LV ejec-
tion fraction (EF), -AR block-
ade is associated with a survival
benefit with or without coronary
artery disease (10).
In humans with moderate to
severe degenerative MR, 14-day
treatment with 1-AR blockade
decreases LV work, but with in-
creases in LV end-diastolic vol-
me (EDV) and end-systolic volume (ESV) and no change
n LV EF (11). However, the beneficial effect of 1-AR
blockade on LV function in heart failure is achieved after
long-term therapy, and there has not been a human trial of
extended 1-AR blockade on LV remodeling and function
n patients with isolated MR. Therefore, the current random-
zed, controlled study used magnetic resonance imaging (MRI)
ith tissue tagging and 3-dimensional (3D) analysis as a
urrogate outcome to evaluate the effects of long-term 1-AR
blockade on LV remodeling and function in patients with
chronic, isolated MR.
Methods
Study population. Eligible patients had moderate or severe
MR documented by color flow Doppler, LV EF of more
than 55%, LV end-systolic dimension of 40 mm, and
echocardiographic thickening of the mitral valve leaflets and
prolapse. Patients were excluded with New York Heart
Association functional class III or IV symptoms, previous
myocardial infarction, significant coronary artery disease by
exercise testing with myocardial perfusion imaging, signif-
icant other valvular disease, serum creatinine level of more
than 2.5 mg/dl, and hypertension requiring medical treat-
ment. The study was approved by the University of Alabama
Institutional Review Board, and all subjects gave written
informed consent.
Study protocol. We conducted a randomized, double-
blind study with 2 years of treatment of 1-AR blockade
with Toprol XL (AstraZeneca, London, United Kingdom)
(range: 25 to 100 mg/day) versus placebo in patients with
moderate to severe MR. Toprol XL was administered with
a starting dose of 12.5 to 25 mg/day and was titrated as
tolerated at 2-week intervals to a maximum of 100 mg/day.
After randomization, patients underwent MRI scanning,
which was repeated at 6, 12, 18, and 24 months after
randomization. MRI also was performed in control volun-
Abbreviations
and Acronyms
AR  adrenergic receptor
BSA  body surface area
CI  confidence interval
3D  3-dimensional
ED  end-diastolic
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
LV  left ventricular
MR  mitral regurgitation
MRI  magnetic resonance
imagingteers (mean age: 52  11 years, range: 35 to 70 years) whoad no prior history of cardiovascular disease and were not
aking any cardiovascular medications.
ardiac MRI. As previously described (12,13), MRI was
erformed on a 1.5-T MRI scanner (Signa GE Healthcare,
ilwaukee, Wisconsin) optimized for cardiac application.
he short axis volumes defined by the contours, excluding
apillary muscles, were summed to calculate LV volume
12,13). LV volume-time curves were constructed and
ifferentiated with respect to time to obtain peak diastolic
lling rates (13).
Three-dimensional LV geometric parameters were mea-
ured from surfaces fit to endocardial and epicardial con-
ours manually traced near end-diastole and end-systole. 3D
all thickness was computed by measuring the perpendic-
lar distance from a point on the endocardial surface to the
losest point on the epicardial surface.
Tagged MRI scans were acquired with repetition times of
ms, echo times of 4.4 ms, and tag spacing of 7 mm. 3D
V strain was measured from tagged images at end-systole,
hich was defined by visual inspection of the image data as
he time frame with maximum contraction (14). Two-
imensional strain rates were measured using harmonic phase
nalysis (15), which measures local myocardial 2-dimensional
train based on the local spatial frequency of tag lines. Strain
nd strain rates were computed at each segment in the
merican Heart Association 17-segment model and were
veraged over the mid-ventricular segments.
tatistical analysis. PRIMARY OUTCOME VARIABLES.
Analyses of MRI scans were performed blinded and side by
side in 1 sitting for each patient. MRI outcome variables
were categorized according to the following: 1) LV geom-
etry: LV end-diastolic volume (EDV)/body surface area
(BSA), LV ED mass/LV EDV, 3D LV ED radius/wall
thickness (midwall); 2) LV systolic function: LV EF, LV
ESV/BSA, 2-dimensional LV systolic longitudinal strain
rate; and 3) LV diastolic function: LV peak early filling rate
(EDV/s).
ANALYSIS. The t test (for continuous variables) and Fisher
exact test (for categorical variables) were used to compare
demographic characteristics, clinical characteristics, and
outcome variables at baseline between the 2 groups. Treat-
ment differences in the rate of progression, assessed on an
intention-to-treat basis, was the focus of the comparisons
over time between the treatment groups. Rate of progres-
sion for each outcome was modeled with SAS PROC
MIXED (SAS Institute, Cary, North Carolina) assuming
the best working correlation structure based on the Bayesian
information criterion from the choices of autoregressive lag
1, heterogeneous autoregressive lag 1, compound symmetry,
and heterogeneous compound symmetry. Compound sym-
metry was found to be the best structure for all outcomes
except for LV EDV/BSA, where autoregressive lag 1 was
found to be the best structure. A significant interaction
effect between the linear component of time and the
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August 28, 2012:833–8 1-Receptor Blockade for Chronic MRtreatment group was the measure of treatment effect, as-
sessed at p  0.05.
MRI examinations were performed at 6-month intervals
over the 2-year study period. To achieve a more accurate
representation of a patient’s rate of progression over time,
the actual time of the MRI relative to randomization that is
closest to a 3-month interval (i.e., 0, 3, 6, 9, 12, 15, and so on)
was used in the analysis, instead of the target 6-month visit.
For example, if a patient was scheduled to have a 12-month
MRI but actually underwent an MRI examination 2.5
months late from the target visit, the time associated with
the MRI data for this visit was considered to be at 15
months, instead of 12 months.
Results
Demographic data. Demographic data are summarized in
Table 1. Thirty-eight patients were enrolled: 19 in the
placebo group and 19 in the Toprol group. One patient in
the placebo group dropped out soon after the randomiza-
tion, and 1 patient in the Toprol group died of pulmonary
embolus after cosmetic surgery shortly after the 12-month
visit. Thus, 36 patients had 2 years of follow-up data.
However, these patients were included in the random effects
models on an intention-to-treat principle.
Baseline age, sex, race, heart rate, or blood pressure did
not differ between groups. Of the 38 MR patients, 10 had
holosystolic murmurs, with 5 in treated patients and 5 in
untreated patients. No patients had a flail leaflet. No
patients had atrial fibrillation, and all patients were New
York Heart Association functional class I or II, with 90%
and 95% of placebo and treatment groups being in New
York Heart Association class I, respectively.
Baseline Demographic and Clinical Characteristicsof Patients with Isolated Mitral RegurgitationTable 1 Baseline Demog phic and Clinical Characteristicsof Patients with Isolated Mitral Regurgitation
Variable Placebo Toprol p Value
N 19 19
Female 9 (47%) 11 (58%) 0.7459
White race 19 (100%) 16 (84%) 0.2297
Age (yrs) 56 9.2 52.9 9.1* 0.3101
Systolic blood pressure (mm Hg) 121 14 125 14 0.3859
Diastolic blood pressure (mm Hg) 75 11 75 8 0.8905
Heart rate (beats/min) 67 12 66 11 0.8238
NYHA functional class I 17 (90%) 18 (95%) 1.0000
MRI variables
LV EDV/BSA (ml/m2) 92 17 96 20 0.4964
LV ED mass/LV EDV (gm/ml) 0.61 0.13 0.61 0.12 0.9720
LV ED radius/wall thickness 4.76 0.92 4.69 0.92 0.8001
LV EF (%) 63 5 62 6 0.7820
LV ESV/BSA (ml/m2) 34 7 36 8 0.4258
Peak systolic longitudinal
strain rate (%/s)
88 27 83 29 0.5619
Peak early filling rate (EDV/s)* 2.27 0.61 2.12 0.57 0.4139
Values are n (%) or mean SD. *Peak early filling rate (milliliters per second) normalized to EDV.
BSA  body surface area; EDV  end-diastolic volume; ESV  end-systolic volume; LV  leftt
entricular; ED  end-diastolic; EF  ejection fraction; MRI  magnetic resonance imaging;
YHA  New York Heart Association.At baseline, MR patients had 35% higher LV EDV/
BSA, 50% higher LV ESV/BSA, 33% higher LV stroke
volume/BSA, and 18% lower LV ED mass/EDV ratio,
whereas LV EF was slightly lower in MR patients versus
control subjects (Online Fig. 1, Online Tables 1 to 4).
Analyses of outcomes. First-order and second-order poly-
nomials for time effects were fitted for all outcome variables,
and coefficients associated with the second-order terms were
not found to be significant. Therefore, a first-order (linear)
time effect model was used. Figures 1, 2, and 3 display the
raw data by treatment group for each LV outcome with the
fitted lines as well as the fit with 95% confidence bands
based on individual confidence intervals for the means at
each time point. Table 2 displays the estimates and standard
rrors for the annual rates of progression (slope  12
onths) for each group including the p values, which
ompare the estimates between the 2 groups.
There were no significant treatment effects found on LV
DV/BSA (p  0.457), LV ED mass/EDV (p  0.1967),
or LV ED 3D radius/wall thickness (p  0.55). Significant
treatment effects were identified on LV EF (p  0.006),
whereas no significant treatment effects were found on LV
ESV/BSA (p  0.214) or LV systolic longitudinal strain
ate (p  0.16). The slope of LV EF per month for the
oprol group was estimated to be 0.04 (95% confidence
nterval [CI]: 0.08 to 0.16, not significantly different from
), whereas the slope of the placebo group was estimated to
e 0.21 (95% CI: 0.33 to 0.08, significantly different
rom 0, p  0.001). This implies that the LV EF for the
lacebo group after 2 years is expected to decrease by as little
s 1.92% and as much as 7.92%, on average, with 95%
onfidence. Significant treatment effects were detected for
V diastolic function measured by the peak early filling rate
rom the MRI volume time curves (p  0.001). The slope
or the Toprol group was estimated to be 0.008 (95% CI:
0.002 to 0.017), whereas the slope for the placebo
roup was estimated to be 0.015 (95% CI: 0.02 to
0.005). In addition, there was a treatment effect for
eart rate (p  0.006) and systolic blood pressure (p 
.03) in the placebo group versus the Toprol-treated MR
atients (Online Fig. 2).
ensitivity analyses. Sensitivity analyses were performed
o account for a possible effect in the statistical analyses of
articipants who had undergone mitral valve surgery. These
atients are identified (black lines) in Figures 1, 2, and 3. Surgery
s performed because it is expected that the patient’s
ondition will improve. Therefore, it is logical to assume
hat the data observed after surgery of the patients who
nderwent mitral valve repair or replacement is better than
hat it would have been if they did not undergo surgery;
ence, the data after surgery were replaced with the worst
alue for the visit within the treatment group. The conclu-
ions were the same.
dverse events. Although generally there was a pattern of
higher adverse event or serious adverse event frequency inhe placebo group, by design the study was not powered to
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1-Receptor Blockade for Chronic MR August 28, 2012:833–8detect modest differences between groups. Twelve of the 19
patients randomized to placebo and 8 of the 19 patients
randomized to Toprol experienced at least 1 adverse event.
Seven of the 12 in the placebo group and 3 of the 8 in the
Toprol group experienced serious adverse events. A formal
test of the hypothesis using the Fisher exact test did not
show this difference to be statistically significant (p  0.33
or adverse event and p  0.27 for serious adverse event).
Figure 1 Changes in Left Ventricular End-Diastolic
Volumes and Geometry Over 2 Years
Treatment efficacy is shown by the difference in rates of progression (slopes of
the red lines) between the placebo and Toprol groups. The blue-shaded area
represents the 95% confidence intervals for the mean outcome at a given time
point. Individual patient data over time are shown for those with surgery (black
solid lines before surgery and broken lines after surgery) and without surgery
(yellow). There was no treatment effect for left ventricular (LV) end-diastolic
volume (EDV)/body surface area (BSA), LV ED mass/LV EDV ratio, or LV ED
3-dimensional radius/wall thickness.ix of the 19 patients in the placebo group and only 2 of the9 in the Toprol group had undergone mitral valve repair or
eplacement. The Fisher exact test also did not show this
ifference to be statistically significant (p  0.23).
iscussion
n this randomized placebo-controlled study, chronic
1-AR blockade prevented the progressive decline of LV
EF, whereas LV EF slope decreased in the placebo group.
At randomization, all patients were within standard echo-
cardiographic guidelines, with an LV end-systolic dimen-
sion of less than 40 mm and an LV EF of more than 55%
in the absence of symptoms. The beneficial effects of 1-AR
Figure 2 Changes in LV Systolic Function Over 2 Years
There was a significant treatment effect for LV ejection fraction (EF), but not for
LV end-systolic volume (ESV)/BSA or LV peak systolic longitudinal strain rate.
(See Fig. 1 for details.) Abbreviations as in Figure 1.
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August 28, 2012:833–8 1-Receptor Blockade for Chronic MRblockade persist on an intention-to-treat basis and with a
sensitivity analysis. There is no difference in the rate of
progression for systolic wall stress calculated using blood
pressure and 3D radius/wall thickness at the base, mid, or
distal LV (data not shown). Thus, the tendency for an
increase in LV ESV in the placebo group resulting in a
decrease in the slope of LV EF may represent a decrease in
contractility. In parallel with the effects on LV systolic
function, early LV diastolic filling rate demonstrates a
decreasing slope in placebo and an increasing slope in
treated patients.
No treatment effects were detected for LV remodeling.
The discordance between LV remodeling and improved LV
systolic function with 1-AR also has been reported in the
canine model of isolated MR (8,9). The dog model of
isolated MR is marked by loss of extracellular matrix
components essential to cardiac geometry (16,17), decrease
in protein synthesis (18), and decrease in profibrotic growth
factors, including transforming growth factor- (16). Thus,
xtracellular matrix loss combined with a less robust hyper-
rophy response produces LV wall thinning and a decrease
n LV EDV mass/volume ratio (16,17), as in our MR study
atients (Online Tables 1 to 4). These myocardial responses
re a poor match for antifibrotic and antihypertrophic effects
f renin-angiotensin system blockade, which explains why
his therapy or vasodilators do not attenuate LV remodeling
n isolated MR (2,3). Although 1-AR blockade improves
V and cardiomyocyte function in the MR dog, interstitial
ollagen loss is unchanged, which may explain the failure to
ttenuate LV dilatation (9).
1-AR blockade exhibits a trend toward preventing the
need for operative intervention; however, the current study
is not powered adequately to evaluate this outcome. Of
interest, Figure 1 demonstrates baseline MRI-derived LV
EF of less than 55% in 3 patients who received 1-AR
Figure 3 Changes in LV Diastolic Function Over 2 Years
There was a significant treatment effect for peak early left ventricular (LV) diastolic
filling rate. (See Fig. 1 for details.)blockade. The discrepancy between echo-derived LV end-systolic dimension and fractional shortening and MRI
volume-based LV EF likely resides in the mid and apical
spherical remodeling distal to standard echo-derived LV
end-systolic dimension at the tips of the papillary muscles
(19). Online Figure 1 and Online Tables 1 to 4 demon-
strate the greater amount of LV apical spherical remod-
eling, which contributes to increased LV ESV. Never-
theless, LV EF slope was positive in the treated group,
further supporting the beneficial effect of 1-AR block-
de in isolated MR.
We do encourage caution that spurious findings may have
risen from the multiple statistical tests conducted for the 7
utcomes considered in this report. Because this was a pilot
tudy, it was not clear at the inception what adjustments
ere appropriate to protect from the possibility of these
purious findings. However, even the most conservative
pproach, a Bonferroni adjustment with alpha of 0.0071
0.05/7), subsequently was shown not to affect the interpre-
ation of the findings, because all factors significant at 0.05
lso were significant at this strict level. In addition, as noted
n the statistical methods, multiple correlation structures
ay be used to analyze the data. The choice of an appro-
riate structure was based on a priori and objective criteria
f goodness-of-fit indices for the model using that particular
orking correlation and were not based on treatment differ-
nces in the outcome measures. Thus, it is worth noting that
sing autoregressive structures considered or using actual times
hen MRI was undertaken resulted in no significant differ-
nces in any of the outcomes.
The current study uses cardiac remodeling as a surrogate
utcome to assess the potential beneficial impact of 1-AR
lockade in chronic isolated MR. Although we are con-
inced that the surrogate outcome of LV EF will be related
trongly with important clinical outcomes, including pre-
ention of heart failure and prolonging the need for surgical
ntervention, the current study does not definitively estab-
ish that clinical outcomes will improve, an association that
an be assessed only in a Phase III randomized clinical.
evertheless, this study using LV functional outcome, in
Estimated Annual Rates of Progression(Incre se if Positive and Dec eas if Negative)of Each Outcome for Each Treatment Group
Table 2
Estimated Annual Rate of Progression
(Increase if Positive and Decrease if Negative)
of Each Outcome for Each Treatment Group
Outcome Variable
Slope Estimates (SE)
p ValuePlacebo Toprol
LV EDV/BSA (ml/m2) 2.53 (2.19) 0.25 (2.14) 0.4568
LV ED mass/LV EDV (gm/ml) 0.01 (0.01) 0.00 (0.01) 0.1967
LV ED radius/wall thickness 0.09 (0.06) 0.04 (0.06) 0.5550
LV EF (%) 2.48 (0.75) 0.47 (0.75) 0.0060
LV ESV/BSA (ml/m2) 1.31 (0.81) 0.11 (0.81) 0.2144
Peak systolic longitudinal strain
rate (%/s)
6.48 (3.70) 0.96 (3.73) 0.1587
Peak early filling rate (EDV/s)* 0.18 (0.06) 0.09 (0.06) 0.0011
*Peak early filling rate (milliliters per second) normalized to EDV. p Values are for comparing the
estimates for the groups.
Abbreviations as in Table 1.
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1-Receptor Blockade for Chronic MR August 28, 2012:833–8addition to other reports of a survival benefit in patients
with isolated MR (10), provides empiric support for the use
of 1-AR blockade in patients with chronic degenerative
R. These findings call for a large multicenter clinical trial
o confirm these effects.
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APPENDIX
For supplemental tables and figures,
please see the online version of this article.
